---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-005220"
form_type: "8-K"
ticker: "PBYI"
cik: "0001401667"
company_name: "PUMA BIOTECHNOLOGY, INC."
filed_at: "2023-03-02T23:59:59+00:00"
generated_at: "2026-06-18T14:45:18.657253+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Puma Biotech Q4 net loss $5.6M; FY net income $0; guides FY2023 product rev $205-210M

## Summary
- Q4 product revenue $53.7M (+5% YoY); full year $200.0M (+6% YoY).
- Q4 GAAP net loss $5.6M ($0.12/sh) vs net income $4.2M in Q4 2021; includes $12.4M legal accrual.
- Full year 2022 GAAP net income $0.0M ($0.00/sh) vs net loss $29.1M in 2021.
- Non-GAAP adjusted net income FY2022 $11.8M ($0.26/sh) vs $3.5M ($0.09/sh) in 2021.
- FY2023 guidance: product revenue $205-210M, royalty rev $25-30M, net income $20-24M.

## SEC filing metadata
- accession: 0001437749-23-005220
- form_type: 8-K
- ticker: PBYI
- cik: 0001401667
- company_name: PUMA BIOTECHNOLOGY, INC.
- filed_at: 2023-03-02T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1401667/000143774923005220/0001437749-23-005220-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1401667/000143774923005220/pbyi20230222_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-005220
- JSON: https://secwatch.observer/filing/0001437749-23-005220.json
- Plain text: https://secwatch.observer/filing/0001437749-23-005220.txt

## Key facts
- Earnings Releases
  PUMA BIOTECHNOLOGY, INC. reported the fourth quarter and fiscal year ended December 31, 2022 results: revenue $53.7 million, net income net loss of $5.6 million, or $0.12 per share.
  - Period: the fourth quarter and fiscal year ended December 31, 2022
  - Revenue: $53.7 million
  - Net income: net loss of $5.6 million, or $0.12 per share
  - Result: reported results
  source text: year 2021. Product revenue, net consists entirely of revenue from sales of NERLYNX®, Puma’s first commercial product. Product revenue, net for the fourth quarter of 2022 was $53.7 million, compared to $51.0 million in the fourth quarter of 2021. Product revenue, net for the full year 2022 was $200.0 million, compared to $189.1 million in 2021. Based on accounting
  evidence_url: https://www.sec.gov/Archives/edgar/data/1401667/000143774923005220/0001437749-23-005220-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.